Premium
Acute dose‐response studies in bronchial asthma with a new corticosteroid, budesonide.
Author(s) -
EllulMicallef R,
Johansson SA
Publication year - 1983
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1983.tb01524.x
Subject(s) - budesonide , asthma , corticosteroid , medicine , inhalation , glucocorticoid , anesthesia , respiratory disease , pharmacology , lung
1 Budesonide is an epimeric mixture of a new synthetic non‐halogenated glucocorticoid (16 alpha, 17 alpha,‐(22R,S)‐prophylmethylenedioxypregna‐ 1,4‐diene‐11/3,21‐diol‐3, 20‐dione). 2 Acute dose response studies with three different inhaled doses of budesonide, have been carried out in a group of 12 chronic asthmatic patients. 3 The lowest dose (100 micrograms) of inhaled budesonide produced a more marked effect in relieving airflow obstruction, than a much larger (1600 micrograms) oral dose of the drug. 4 When the area under the curve for peak expiratory flow rate values was calculated, a dose‐response relationship could be seen between the different inhaled doses. 5 It appears that budesonide has a predominantly local anti‐asthmatic action in the lung.